Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

[1]  Trina E. Chang,et al.  Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation , 2017, The Australian and New Zealand journal of psychiatry.

[2]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[3]  E. Brown,et al.  Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. , 2016, The Journal of clinical psychiatry.

[4]  K. Hashimoto.  Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity , 2016, Psychological Medicine.

[5]  K. Hashimoto,et al.  Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine , 2016, Psychiatry Research.

[6]  D. Ma,et al.  Prenatal ketamine exposure causes abnormal development of prefrontal cortex in rat , 2016, Scientific Reports.

[7]  K. Hashimoto,et al.  Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[8]  R. Shelton,et al.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.

[9]  Keith M. Harris,et al.  Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications , 2016, BMC medical ethics.

[10]  P. Popik,et al.  Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor , 2015, Neuropharmacology.

[11]  H. Manji,et al.  Husseini Manji , 2015, Nature Reviews Drug Discovery.

[12]  R. Matsumoto,et al.  Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review , 2015, Neuropsychiatric disease and treatment.

[13]  K. Hashimoto,et al.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects , 2015, Translational Psychiatry.

[14]  A. Arnsten,et al.  Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish , 2015, CNS Spectrums.

[15]  D. Charney,et al.  A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder , 2014, Biological Psychiatry.

[16]  V. Wong,et al.  One‐stop clinic for ketamine‐associated uropathy: report on service delivery model, patients' characteristics and non‐invasive investigations at baseline by a cross‐sectional study in a prospective cohort of 318 teenagers and young adults , 2014, BJU international.

[17]  D. Luckenbaugh,et al.  Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. , 2014, The Journal of clinical psychiatry.

[18]  R. Howland,et al.  The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review , 2014, Current neuropharmacology.

[19]  Yuantao Li,et al.  Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring , 2014, Neurobiology of Disease.

[20]  R. Lam,et al.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes , 2014, Psychological Medicine.

[21]  John R Geddes,et al.  Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic , 2014, Journal of psychopharmacology.

[22]  M. Kuskowski,et al.  Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. , 2014, Journal of affective disorders.

[23]  K. Hashimoto,et al.  R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine , 2014, Pharmacology Biochemistry and Behavior.

[24]  Dan V Iosifescu,et al.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.

[25]  H. Akiskal,et al.  Affective temperaments and hopelessness as predictors of health and social functioning in mood disorder patients: a prospective follow-up study. , 2013, Journal of affective disorders.

[26]  H. Möller,et al.  Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series , 2013, Journal of clinical pharmacology.

[27]  Dennis S. Charney,et al.  Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.

[28]  Beatriz Paniagua,et al.  Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver , 2013, Neuron.

[29]  Brian A Palmer,et al.  Serial infusions of low-dose ketamine for major depression , 2013, Journal of psychopharmacology.

[30]  S. Gupta,et al.  Illicit ketamine and its bladder consequences: is it irreversible? , 2012, BMJ Case Reports.

[31]  Z. Cai,et al.  Ketamine-Associated Urinary Tract Dysfunction: An Underrecognized Clinical Entity , 2012, Urologia Internationalis.

[32]  Tao Zhang,et al.  Effects of Propofol and Ketamine as Combined Anesthesia for Electroconvulsive Therapy in Patients With Depressive Disorder , 2012, The journal of ECT.

[33]  D. Luckenbaugh,et al.  Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial , 2012, Biological Psychiatry.

[34]  Nanxin Li,et al.  Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure , 2011, Biological Psychiatry.

[35]  E. Domino.  Taming the Ketamine Tiger , 2010, Anesthesiology.

[36]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[37]  Wei Hao,et al.  Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. , 2010, Brain : a journal of neurology.

[38]  P. O’Donnell,et al.  Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine , 2010, Neuropsychopharmacology.

[39]  M. Behrens,et al.  Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia , 2008, The Journal of Neuroscience.

[40]  C. Man,et al.  The destruction of the lower urinary tract by ketamine abuse: a new syndrome? , 2008, BJU international.

[41]  K. Tsai,et al.  Ulcerative cystitis associated with ketamine. , 2008, The American journal on addictions.

[42]  J. Lisman,et al.  Prolonged Exposure to Nmdar Antagonist Suppresses Inhibitory Synaptic Transmission in Prefrontal Cortex Animal Model and Brain Slices Preparation , 2022 .

[43]  D. Pinault,et al.  N-Methyl d-Aspartate Receptor Antagonists Ketamine and MK-801 Induce Wake-Related Aberrant γ Oscillations in the Rat Neocortex , 2008, Biological Psychiatry.

[44]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[45]  J. Cramer,et al.  Psychiatric safety of ketamine in psychopharmacology research , 2007, Psychopharmacology.

[46]  C. Morgan,et al.  Acute and chronic effects of ketamine upon human memory: a review , 2006, Psychopharmacology.

[47]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[48]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[49]  Danielle C. Turner,et al.  Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task , 2005, Psychopharmacology.

[50]  E T Bullmore,et al.  Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. , 2005, Cerebral cortex.

[51]  V. Jevtovic-Todorovic,et al.  The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain , 2005, Neurobiology of Aging.

[52]  A. Belger,et al.  Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine , 2005, Psychopharmacology.

[53]  P S Pine,et al.  Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[54]  C. Morgan,et al.  Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. , 2004, Drug and alcohol dependence.

[55]  C. Streutker,et al.  Ketamine-associated ulcerative cystitis: a new clinical entity. , 2004, Urology.

[56]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[57]  S. Sagar,et al.  Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity , 2003, Epilepsy & Behavior.

[58]  D. Schulz,et al.  Prolonged effect of an anesthetic dose of ketamine on behavioral despair , 2002, Pharmacology Biochemistry and Behavior.

[59]  K. Sunagawa,et al.  Effects of Ketamine on In Vivo Cardiac Sympathetic Nerve Endings , 2001, Journal of cardiovascular pharmacology.

[60]  J. Olney,et al.  A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide , 2001, Brain Research.

[61]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[62]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[63]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[64]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[65]  P. Eide,et al.  Reply to S.T. Meller: Ketamine: relief from chronic pain through actions at the NMDA receptor. , 1997, Pain.

[66]  P. Eide,et al.  Comments on Cervero and Laird, PAIN, 68 (1996) 13-23: PAIN 3263 , 1997 .

[67]  K. L. Leenders,et al.  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) , 1997, European Neuropsychopharmacology.

[68]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[69]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[70]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[71]  David J. Smith,et al.  Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro , 1987, Neuropharmacology.

[72]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[73]  D. Lodge,et al.  Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine , 1982, Neuroscience Letters.

[74]  S. Zukin,et al.  Adverse reactions to ketamine Anaesthesia , 1981, Anaesthesia.

[75]  J. Horáček,et al.  Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. , 2013, Neuro endocrinology letters.

[76]  Richard B. Darlington,et al.  Web-based method for translating neurodevelopment from laboratory species to humans , 2007, Neuroinformatics.

[77]  Y. Katz,et al.  SINGLE-DOSE KETAMINE ADMINISTRATION INDUCES APOPTOSIS IN NEONATAL MOUSE BRAIN , 2005, Journal of basic and clinical physiology and pharmacology.

[78]  B. Brandner,et al.  Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers , 2004, Neuropsychopharmacology.

[79]  S. Kapur,et al.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia , 2002, Molecular Psychiatry.

[80]  S. T. Meller.  Ketamine: relief from chronic pain through actions at the NMDA receptor? , 1996, Pain.